Susan M. Domchek, MD
The combination of olaparib (Lynparza) and durvalumab (Imfinzi) demonstrated a disease control rate (DCR) of 80% for pretreated patients with germline BRCA-
mutated (gBRCAm), HER2-negative metastatic breast cancer, according to phase II findings from the MEDIOLA trial presented at the 2017 San Antonio Breast Cancer Symposium.1
The phase II DORA trial is planned to further assess the combination of olaparib and durvalumab for patients with platinum-treated triple-negative breast cancer. This trial plans to enroll 60 participants with a primary endpoint of PFS. The estimated primary completion date for the trial is October 2019 (NCT03167619).
- Domchek SM, Postel-Vinay S, Bang Y-J, et al. An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC). Presented at: the 2017 San Antonio Breast Cancer Symposium; Dec. 5-9, 2017. Abstract PD6-11.
- Robson M, Im S-A, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377:523-533.
... to read the full story